Tyra Biosciences, Inc.
NASDAQ:TYRABiotechnology
-$0.72 today
- Market cap
- $1.35B
- Beta
- 0.75
- P/E (TTM)
- -13.4
- EPS (TTM)
- -$2.12
Volume 0.47M
Average 0.96M
TYRA Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Tyra Biosciences, Inc.NASDAQ: TYRA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $138K fell 3.5% year over year, behind the +0.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.5% from the prior quarter. Over 3 fiscal years it compounded at +22.6% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -3.5% toward the trailing-twelve-month pace of +0.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 546K USD
- Year-over-year change
- +5.2%
- 4-year CAGR
- +40.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 546K | +5.2% |
| FY2024 | 2024-12-31 | 519K | +45.4% |
| FY2023 | 2023-12-31 | 357K | +20.6% |
| FY2022 | 2022-12-31 | 296K | +111.4% |
| FY2021 | 2021-12-31 | 140K | — |
Depreciation & Amortization vs competitors
How TYRA compares with its peers on the latest reported figures
- TYRA's LTM Mar 2026 depreciation & amortization of $541K is the 8th highest of the 11 companies compared; the peer median is $1.17M.
- Its year-over-year change of +0.2% is the 7th highest of 10, against a peer median of +3.5%.
- Over three fiscal years its annual growth of +22.6% compares with a peer median of +34.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Mar 2026 | $2.79M | -10.3% | +0.1% | 9.9% | |
| LTM Jun 2026 | $2.15M | +104.9% | +106.0% | 1.3% | |
| LTM Mar 2026 | $2.03M | -0.8% | +34.1% | 9.4% | |
| LTM Mar 2026 | $1.19M | +3.5% | +8.1% | — | |
| LTM Mar 2026 | $1.15M | +34.0% | +10.8% | 1.6% | |
| LTM Mar 2026 | $997K | +3223.3% | +83.4% | 2.0% | |
| LTM Mar 2026 | $541K | +0.2% | +22.6% | — | |
| LTM Mar 2026 | $314K | +2.6% | +49.5% | — | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $130K | +109.7% | +119.0% | — |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding TYRA) | $1.17M | +3.5% | +34.1% | 3.3% | |
Competitors are the stored peer set for TYRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
| Selling, General & Admin | 5.65M | 15.92M | 17.43M | 24.1M | 29.83M |
| Operating Expenses | 26.29M | 58.93M | 79.95M | 104.18M | 132.76M |
| Depreciation & Amortization | 140K | 296K | 357K | 519K | 546K |
| EBITDA | (26.15M) | (55.03M) | (68.78M) | (85.96M) | (119.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (26.29M) | (58.93M) | (79.95M) | (104.18M) | (132.76M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 3.65M | 10.81M | 17.7M | 12.82M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (6K) | 3.6M | 10.81M | 17.7M | 12.82M |
| Income Before Tax | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (26.29M) | (55.33M) | (69.13M) | (86.48M) | (119.95M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| EPS (Diluted) | (0.63) | (1.23) | (1.62) | (1.51) | (2.01) |
| Weighted Avg Shares | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
| Weighted Avg Shares (Diluted) | 41.44M | 41.88M | 42.7M | 57.22M | 59.6M |
Tyra Biosciences, Inc.
NASDAQ:TYRA
Intrinsic Alpha fair value
Locked
Current Price
$19.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.